JAK2 mutations (more recurrently c.2047A > G and p.R683G) were enriched in BCR-ABL1-like ALL patients [9/14(64%) vs non-BCR-ABL1-like 3/28(11%), P = 0.001]. The gene discussed is JAK2; the disease is acute lymphoblastic leukemia.